The GORE CARDIOFORM ASD Occluder achieved a 6-month composite clinical success rate of 87.6% and 100% closure success among patients with 6-month imaging.
Does transcatheter closure using the GORE CARDIOFORM ASD Occluder achieve closure and composite clinical success in patients with ostium secundum atrial septal defects?
The GORE CARDIOFORM ASD Occluder demonstrated high rates of successful ASD closure and composite clinical success up to 36 months, despite a high incidence of benign wire frame fractures.
BACKGROUND: The GORE CARDIOFORM ASD Occluder (GCA, W. L. Gore NCT02985684).
Qureshi et al. (Wed,) conducted a other in ostium secundum atrial septal defect (ASD) (n=569). GORE CARDIOFORM ASD Occluder was evaluated on 6-month closure success and composite clinical success. The GORE CARDIOFORM ASD Occluder achieved a 6-month composite clinical success rate of 87.6% and 100% closure success among patients with 6-month imaging.